Health
Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19 – Loma Linda University Health
ACTIV-2 is studying multiple early COVID-19 treatments
Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19.Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…
-
Noosa News22 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General23 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out
-
Noosa News21 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
General18 hours agoJordan Thompson retires from Wimbledon round-of-16 match with American Taylor Fritz